SONM

#4930
DNA X, Inc. - Common Stock
3.2 8 USD
+0.01%
Sektor: Technologie
Basis: USD
Gewinnwährung: USD
Tagesspanne
3.28
3.28
Jahresspanne
2.62
6.14
Tagesänderung
+0.92%
Monatliche Änderung
-36.31%
6 month change
-43.55%
Jahresänderung
-43.55%
Vorheriger Schlusskurs
3.2 5
Open
3.2 8
Tief
3.2 8
High
3.2 8
Volumen
1
Vollständige Grafik anzeigen

Financials

Übersicht Finanzbericht Statistik Documents

2026

Current report, Q2 FY2026
DNA X, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
DNA X, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
DNA X, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
DNA X, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
DNA X, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
DNA X, Inc. current report, Q2 FY2026
8-K
Quarterly report, Q1 FY2026
DNA X, Inc. quarterly report, Q1 FY2026
10-Q
Current report, Q1 FY2026
DNA X, Inc. current report, Q1 FY2026
8-K
Current report, Q1 FY2026
DNA X, Inc. current report, Q1 FY2026
8-K
Current report, Q1 FY2026
DNA X, Inc. current report, Q1 FY2026
8-K

DNA X, Inc. current report, Q3 FY2024

Business Context and Reporting Period

This Form 8-K filing by Sonim Technologies, Inc. (trading symbol: SONM) was submitted on August 6, 2024. The report details the entry into a material definitive agreement regarding the potential sale of common stock. Note: The request metadata references "DNA X, Inc.," but the filing text explicitly identifies the registrant as Sonim Technologies, Inc.

Key Financial Metrics

This filing does not report revenue, profit, cash flow, margins, debt, or liquidity metrics. It is a current report focused on a specific corporate action rather than periodic financial performance.

Material Changes and Agreements

  • Sales Agreement: On August 6, 2024, the Company entered into an "at-the-market" (ATM) sales agreement with Roth Capital Partners, LLC.
  • Offering Size: The Company may sell shares of common stock with an aggregate offering price of up to $8,943,000.
  • Commission: The Agent will receive a commission of 3.0% of the gross proceeds from any shares sold.
  • Pricing: Sales will be made at prevailing market prices at the time of sale.
  • Obligations: Neither the Company nor the Agent is obligated to sell or buy any shares under this agreement.

Guidance, Outlook, and Risks

The filing provides no financial guidance or outlook. Key risks and contingencies include:

  • Uncertainty of Sale: No assurance is given that the Company will sell any shares, nor is there certainty regarding the price, amount, or timing of any potential sales.
  • Indemnification: The Company agreed to indemnify the Agent against certain liabilities under the Securities Act of 1933 and the Securities Exchange Act of 1934.
  • Termination: Either party may terminate the Sales Agreement at any time upon specified prior written notice.
  • Registration: Shares will be issued pursuant to an effective shelf registration statement on Form S-3 filed on April 9, 2024.

Investor Verification Checklist

  • Verify the current share price and trading volume of SONM to assess the potential dilution impact of the $8.943 million offering.
  • Review the Company's recent cash position and liquidity needs to understand the motivation for this ATM facility.
  • Monitor future filings to determine if and when shares are actually sold under this agreement.
  • Confirm the total number of authorized but unissued shares available for sale under the existing shelf registration.

Nachrichten